Morphic Holding (MORF) Plans to Raise $75 Million in June 27th IPO
In the last year, Morphic Holding generated $9.4 million in revenue and had a net loss of $23.9 million. Morphic Holding has a market cap of $4.3 billion.
Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.
Morphic Holding provided the following description of their company for its IPO: ” We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies. “.
Morphic Holding was founded in 2014 and has 65 employees. The company is located at 35 Gatehouse Drive, A2, Waltham, MA 02451, US and can be reached via phone at (781) 996-0955 or on the web at http://www.morphictx.com.
Receive News & Ratings for Morphic Holding Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic Holding and related companies with MarketBeat.com's FREE daily email newsletter.